Kemp Maddie, Capriola Ashley, Schauer Stephanie
Wisconsin Division of Public Health, 1 West Wilson St., Madison, WI, United States.
Wisconsin Division of Public Health, 1 West Wilson St., Madison, WI, United States.
Vaccine. 2025 Feb 15;47:126674. doi: 10.1016/j.vaccine.2024.126674. Epub 2025 Jan 4.
Respiratory syncytial virus (RSV) is the leading cause of hospitalizations among infants in the United States. New strategies to prevent RSV among infants and high-risk young children include the maternal RSVpreF vaccine (Abrysvo, Pfizer Inc.) and nirsevimab (Beyfortus, Sanofi and AstraZeneca), a long-acting monoclonal antibody. We examined immunization coverage among infants born during the 2023-24 RSV season and pregnant persons utilizing data from the Wisconsin Immunization Registry and Office of Vital Records to evaluate uptake of both products and overall infant protection against RSV. 5056 (18.2 %) infants received nirsevimab and 4767 (17.2 %) persons who gave birth during this timeframe received the maternal RSVpreF vaccine; 0.8 % of parent-infant dyads received both products. Overall, 36.2 % of infants were protected from RSV. These findings suggest that improved efforts on several fronts are needed to ensure equitable and timely access to both RSV products while also increasing the number of infants protected against RSV.
呼吸道合胞病毒（RSV）是美国婴儿住院的主要原因。预防婴儿和高危幼儿感染RSV的新策略包括母体RSVpreF疫苗（Abrysvo，辉瑞公司）和长效单克隆抗体nirsevimab（Beyfortus，赛诺菲和阿斯利康）。我们利用威斯康星州免疫登记处和生命统计办公室的数据，调查了2023 - 24年RSV季节出生的婴儿和孕妇的免疫接种覆盖率，以评估这两种产品的使用情况以及婴儿对RSV的总体保护情况。5056名（18.2%）婴儿接受了nirsevimab，在此期间分娩的4767名（17.2%）孕妇接受了母体RSVpreF疫苗；0.8%的母婴对接受了两种产品。总体而言，36.2%的婴儿受到了RSV的保护。这些发现表明，需要在多个方面做出更大努力，以确保公平、及时地获得这两种RSV产品，同时增加受到RSV保护的婴儿数量。
